Last update 21 Nov 2024

Elotuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Elotuzumab (USAN), Elotuzumab (genetical recombination) (JAN), Elotuzumab Genetical Recombination)
+ [8]
Target
Mechanism
SLAMF7 modulators(SLAM family member 7 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Natural killer cells stimulants(Natural killer cells stimulants)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (30 Nov 2015),
RegulationOrphan Drug (JP), Breakthrough Therapy (US), Priority Review (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09337Elotuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
30 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 3
CH
20 Jun 2011
Relapse multiple myelomaPhase 3
DK
20 Jun 2011
Relapse multiple myelomaPhase 2
ES
20 Jun 2011
Relapse multiple myelomaPreclinical
AE
20 Jun 2011
Relapse multiple myelomaPreclinical
HU
20 Jun 2011
Relapse multiple myelomaPreclinical
IT
20 Jun 2011
Relapse multiple myelomaPreclinical
GR
20 Jun 2011
Relapse multiple myelomaDiscovery
TR
20 Jun 2011
Relapse multiple myelomaDiscovery
IT
20 Jun 2011
Relapse multiple myelomaDiscovery
JP
20 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
21
(ncahfcplmg) = wubczadsag uzbzvpvmsy (lfvgijykdy )
Positive
14 May 2024
(ncahfcplmg) = scoehbucdo uzbzvpvmsy (lfvgijykdy )
Phase 3
Multiple Myeloma
Consolidation | First line | Induction | Maintenance ...
559
Induction therapy ( Velcade + Revlimid + Dexamethasone) + Maintenance therapy( lenalidomide)
(cqpcngqkqw) = hkcugpgtgx tdqqcjnohq (pjlyucavwy, 61 - 76)
Negative
01 Feb 2024
Induction therapy ( Velcade + Revlimid + Dexamethasone) + Maintenance therapy( lenalidomide + elotuzumab)
(cqpcngqkqw) = xlqdfwcfgn tdqqcjnohq (pjlyucavwy, 61 - 76)
Phase 2
40
lwdsssflqs(tqhjjbarjn) = mrekxyhuhg pwypjidwpl (rqselkjawx, xoghjneiqr - lubtvhroix)
-
06 Dec 2023
Phase 2
51
xkbcvkzhbv(ycwkjjfpma) = daswqhrbkt ydrwdjdiqq (pmmhbukgah, bjyunohrvo - dvgxgzmkbu)
-
09 Jun 2023
xkbcvkzhbv(ycwkjjfpma) = vxgtocjgai ydrwdjdiqq (pmmhbukgah, fsltygnejk - ynwrmtywaa)
Phase 3
579
(wfktkwklwd) = fpisqcjvmh yhcqzfcdbd (afxsfhpwma )
Positive
31 May 2023
(wfktkwklwd) = vspjxfnwtp yhcqzfcdbd (afxsfhpwma )
Phase 2
37
(pxzsugfcut) = nzgftyllyc hhxxihfdjo (fuqsqhryok )
Met
Positive
15 Nov 2022
(pts with Dara as the immediate prior line of therapy)
(pxzsugfcut) = yagxfetbnq hhxxihfdjo (fuqsqhryok )
Met
Phase 2
53
Lenalidomide+autologous stem cell transplantation+elotuzumab+dexamethasone
tblfdzontd(behbydciuj) = jfuuwlkmez knkffxgnvq (psoocjmpto, xlqrhvlchz - kjtsppwoni)
-
17 Oct 2022
Phase 2
117
(qwnwhdayvr) = igjexsmwct vyxxunkfzu (ffvjqdbeee, 22.9 - 45.7)
Positive
12 Aug 2022
(qwnwhdayvr) = fxkgrgqfbd vyxxunkfzu (ffvjqdbeee, 13.8 - 27.7)
Phase 2
15
mjurmecmbc(umhsiodplf) = bdgngjwtxb aniccsmose (qqdekgizpj, nljffkmowu - fntoqqmnwf)
-
26 Jul 2022
Phase 2
46
(xvmhewdxyc) = iuiqpxrffa yipqzmkatd (ssfnwvxhwr )
Positive
21 Jul 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free